Published ahead of print on June 19, 2008, doi:10.1164/rccm.200802-309OC
© 2008 American Thoracic Society doi: 10.1164/rccm.200802-309OC
Wheezing Rhinovirus Illnesses in Early Life Predict Asthma Development in High-Risk ChildrenDepartments of 1 Pediatrics, 2 Medicine, 3 Biostatistics and Medical Informatics, and 4 Population Health Sciences, University of Wisconsin–Madison; and the 5 Wisconsin State Laboratory of Hygiene, Madison, Wisconsin Correspondence and requests for reprints should be addressed to Daniel J. Jackson, M.D., University of Wisconsin Hospital, 600 Highland Avenue, K4/910, Madison, WI 53792. E-mail: djj{at}medicine.wisc.edu
Rationale: Virus-induced wheezing episodes in infancy often precede the development of asthma. Whether infections with specific viral pathogens confer differential future asthma risk is incompletely understood. Objectives: To define the relationship between specific viral illnesses and early childhood asthma development. Methods: A total of 259 children were followed prospectively from birth to 6 years of age. The etiology and timing of specific viral wheezing respiratory illnesses during early childhood were assessed using nasal lavage, culture, and multiplex reverse transcriptase–polymerase chain reaction. The relationships of these virus-specific wheezing illnesses and other risk factors to the development of asthma were analyzed. Measurements and Main Results: Viral etiologies were identified in 90% of wheezing illnesses. From birth to age 3 years, wheezing with respiratory syncytial virus (RSV) (odds ratio [OR], 2.6), rhinovirus (RV) (OR, 9.8), or both RV and RSV (OR , 10) was associated with increased asthma risk at age 6 years. In Year 1, both RV wheezing (OR, 2.8) and aeroallergen sensitization (OR, 3.6) independently increased asthma risk at age 6 years. By age 3 years, wheezing with RV (OR, 25.6) was more strongly associated with asthma at age 6 years than aeroallergen sensitization (OR, 3.4). Nearly 90% (26 of 30) of children who wheezed with RV in Year 3 had asthma at 6 years of age. Conclusions: Among outpatient viral wheezing illnesses in infancy and early childhood, those caused by RV infections are the most significant predictors of the subsequent development of asthma at age 6 years in a high-risk birth cohort.
Key Words: rhinovirus • respiratory syncytial virus • wheezing • asthma • allergic sensitization
Wheezing viral respiratory illnesses during infancy are often the first clinical manifestation of the most common chronic disease of childhood, asthma. However, many children who wheeze with viral infections during infancy will not go on to develop asthma, suggesting a role for virus- and/or host-specific factors in asthma pathogenesis. Previous work has focused on the potential association of early respiratory syncytial virus (RSV) infections and the subsequent risk for asthma and allergic disease (1, 2). With the availability of more sensitive molecular techniques (3), rhinovirus (RV) has been implicated as an important pathogen in early childhood wheezing. In fact, Kotaniemi-Syrjanen and colleagues implicated RV infections leading to hospitalization during infancy as an early predictor of the subsequent development of asthma (4). More recently, we reported that outpatient RV wheezing illnesses during infancy were the most significant predictors of wheezing through 3 years of age in the Childhood Origins of ASThma (COAST) cohort (5). Similarly, Kusel and associates demonstrated an association between wheezing outpatient RV and/or RSV illnesses in infancy and persistent wheezing at 5 years of age; however, this finding was most significant in children with early allergic sensitization (6). Taken together, these data indicate that illness severity, viral etiology, and allergic sensitization may all contribute to the development of persistent wheezing and/or asthma. However, additional data are needed to more precisely define the relationships of specific viral wheezing episodes in early life on asthma development during childhood. Therefore, in our high-risk birth cohort, we prospectively assessed the relationship between the timing and etiology of wheezing viral respiratory infections in early life and the subsequent development of childhood asthma at 6 years of age. Some of the results of this study have previously been reported as abstracts (7, 8).
Study Subjects A total of 289 newborns were enrolled from November 1998 through May 2000 in the COAST study as previously described (9–11). Of these children, 285, 275, and 259 were followed prospectively for 1, 3, and 6 years, respectively. To qualify, at least one parent was required to have respiratory allergies (defined as one or more positive aeroallergen skin tests) and/or a history of physician-diagnosed asthma. The Human Subjects Committee of the University of Wisconsin approved the study, and informed consent was obtained from the parents. There were no differences in demographic characteristics between those children followed to at least 1 year of age compared with those followed up to 6 years of age (Table E1 of the online supplement).
Nasal Lavage Samples
Viral Diagnostics
Allergen-specific IgE
Aeroallergen Skin Testing
Clinical Definitions
Statistical Methods
Viral Isolates A total of 454 wheezing respiratory illnesses were documented during the first 3 years of life: 153 illnesses in 76 children ages 0–1 year, 155 illnesses in 72 children ages 1–2 years, and 146 illnesses in 63 children in the third year of life. Nasopharyngeal wash specimens were obtained during 442 (97%) of these wheezing illnesses. A viral etiology was identified in 398 (90%) of these specimens. The types of viruses detected during the first 3 years of life included RV (212; 48%), RSV (93; 21%), PIV (51; 12%), MPV (33; 7%), CV (20; 5%), AdV (17; 4%), flu (16; 4%), and EnV (10; 2%). Multiple viruses were identified for 48 wheezing illnesses. The following viruses were recovered from these multiple-virus infections: RV (29; 60%), RSV (20; 42%), MPV (15; 31%), AdV (10; 21%), flu (9; 19%), PIV (8; 17%), CV (7; 15%), and EnV (5; 10%). The pattern of early-life infections was distinct in children diagnosed with asthma at age 6 years (Figure 1). Notably, the frequency of RV-induced wheezing episodes increased over the first 3 years of life for children diagnosed with asthma at age 6 years (P = 0.05), and decreased during the same time period in children without asthma (P = 0.0004) (Figure 1).
Viral Illnesses in Early Childhood and Asthma in the Sixth Year of Life In the sixth year of life, 73 of 259 (28%) children had asthma based on predefined clinical criteria. On the basis of National Asthma Education and Prevention Program (NAEPP) guideline criteria, 35 (48%) of these children had intermittent asthma, 25 (34%) had mild persistent asthma, and 13 (18%) had moderate persistent asthma. Of these 73 children with asthma, 46 (63%) were boys and 27 (37%) were girls. Skin prick testing was performed at age 5 years on 64 of 73 children with asthma; 37 (58%) were positive to at least one allergen. This compares to a sensitization rate of 46% (69 of 149) for the children without asthma at age 6 years (P = 0.12). The relationship between the viral etiology of wheezing illnesses in each of the first 3 years of life and the diagnosis of asthma at age 6 years was analyzed. Because RV and RSV were most frequently identified as the cause of wheezing illnesses, the analysis focused on these two viruses. Children who wheezed with RV during infancy were at greater risk of asthma at age 6 than children who did not wheeze with RV or RSV, regardless of whether they wheezed only with RV (odds ratio [OR], 2.9; 95% confidence interval [CI], 1.1, 7.5) or had additional wheezing illnesses with RSV (OR, 2.7; 95% CI, 1.2, 6.3) during this same time period (Table 1). In contrast, children who wheezed only with RSV during infancy developed asthma at age 6 at a rate similar to those who did not wheeze with RV or RSV (OR, 1.2; 95% CI, 0.4, 3.2) (Table 1).
In the second year of life, RV wheezing illnesses continued to be strongly associated with asthma at age 6 years whether children also wheezed with RSV (OR, 12.7; 95% CI, 2.5, 63.1) or did not (OR, 5.6; 95% CI, 2.4, 12.8) (Table 1). Children who wheezed only with RSV during Year 2 were not at increased risk of asthma at age 6 years (OR, 1.3; 95% CI, 0.4, 3.8) (Table 1). In contrast to the first 2 years of life, children who wheezed only with RSV in Year 3 had a significantly increased risk of asthma at age 6 years (OR, 13.6; 95% CI, 3.4, 54.0) (Table 1). Year 3 RV wheezing illnesses were associated with a dramatically increased risk of Year 6 asthma (OR, 31.7; 95% CI, 10.6, 94.9). Among children with one to two wheezing illnesses, RV wheezing was associated with significantly greater asthma risk than non-RV wheezing (89% [16/18] vs. 55% [16/29], P = 0.02). All children who wheezed three or more times in Year 3 wheezed at least once with RV. When wheezing history during the entire first 3 years of life was considered, wheezing with RSV alone was associated with an increased risk of asthma at age 6 years compared with children who did not wheeze with RV or RSV (OR, 2.6; 95% CI, 1.0, 6.3) (Figure 2). Wheezing with RV, regardless of RSV wheezing history, was associated with a substantially increased risk of asthma at age 6 years compared with children who did not wheeze with either RV or RSV (RV only: OR, 9.8; 95% CI, 4.3, 22.0; and RV and RSV: OR. 10.0; 95% CI. 4.5, 22.2) (Figure 2) Furthermore, wheezing with RV alone or in addition to RSV was associated with significantly greater asthma risk compared with wheezing with RSV alone (RV only: OR, 3.8; 95% CI, 1.4, 10.4; and RV and RSV: OR, 3.9; 95% CI, 1.5, 10.5).
We next compared rates of asthma for children who wheezed during the first 3 years of life with RV with those who wheezed with any other viruses (including RSV). Rates of Year 6 asthma were 9% for nonwheezing children and 31% for children who wheezed only with viruses other than RV (OR, 4.2; 95% CI, 1.8, 9.9). Wheezing with RV, either alone or in addition to other viruses, was associated with a significantly greater asthma risk (58%) compared with children who did not wheeze (OR, 13.1; 95% CI, 6.3, 27). Asthma risk was similar for children who wheezed only with RV (53%) and children who wheezed with RV and other viruses (60%) (P = 0.57). There were no differences between rates of infection as determined by viral recovery from nasal lavage samples performed during scheduled clinic visits during Year 1 for children with and without asthma at age 6 years (asthma, 1.2 ± 1.1, and no asthma, 1.2 ± 1.0 infections/y; P = 0.91). Moreover, RV moderate to severe illnesses (MSI) without wheeze were not associated with increased asthma risk at age 6 (no RV MSI Years 1–3, 12% asthma risk; RV MSI without wheeze Years 1–3, 16% asthma risk; RV MSI with wheeze Years 1–3, 59% asthma risk).
Nonviral Risk Factors and Asthma
Allergic Sensitization, RV Wheezing, and Asthma Aeroallergen sensitization without RV wheezing in Year 1 and RV wheezing without concomitant aeroallergen sensitization were each associated with increased rates of asthma at age 6 years (45 and 39%, respectively; Table 3). Infants with both RV wheezing and aeroallergen sensitization by age 1 year had the highest incidence (86%) of subsequent asthma. Sensitization to aeroallergens did not alter the impact of RV wheezing on subsequent asthma development (interaction P = 0.61).
In the third year of life, RV wheezing illnesses had a more prominent effect on asthma risk (OR, 25.6), whereas aeroallergen sensitization was associated with a smaller, but still significant increase in asthma risk (OR, 3.4) (Table 3). Again, aeroallergen sensitization did not modify the relationship between RV wheezing illnesses and asthma development (interaction P = 0.99).
Wheezing RV illnesses occurring at any time during the first 3 years of life were associated with a nearly 10-fold increase in asthma risk at age 6 years, making them the most significant predictor of asthma development in the high-risk COAST cohort. Interestingly, RSV wheezing illnesses during the first 3 years of life were associated with a smaller increase in asthma risk at age 6 years. In Years 1 and 2, the relationship between viral wheezing and subsequent asthma development was specific to RV. By age 3 years, wheezing with either virus was strongly associated with asthma at age 6; however, RV wheezing remained the strongest predictor. This extends our previous findings by demonstrating that outpatient wheezing illnesses with RV during infancy predict not only persistent wheezing at 3 years of age (5) but also asthma at 6 years of age. A significant advance of this study is the comprehensive identification of the etiology and timing of early childhood respiratory wheezing illnesses during the first 3 years of life, and the prospective link to asthma. Using a combination of conventional and molecular viral diagnostics, we were able to identify a viral etiology for 90% of the wheezing illnesses in the first 3 years of life. This recovery rate compares favorably with other studies (4, 6, 16). Previous results generated by the Tucson Children's Respiratory Study group and others linked RSV lower respiratory tract illnesses in the first 3 years of life with a persistent wheezing phenotype at age 6 years (1, 2). We have confirmed this association; however, with the assistance of more comprehensive molecular techniques, we have clearly demonstrated that RV wheezing illnesses in early childhood confer the greatest risk of asthma at age 6 years. Moreover, the risk of developing asthma after outpatient RSV wheezing illnesses during the first 2 years of life is increased only in those children who also wheeze with RV. In the COAST cohort, RV wheezing and aeroallergen sensitization during Year 1 independently conferred increased risk of asthma at age 6. By Year 3, RV wheezing was a far more robust predictor of asthma development at age 6 than was aeroallergen sensitization. Indeed, nearly 90% of children wheezing with RV at age 3 subsequently developed asthma regardless of the presence or absence of aeroallergen sensitization. Kusel and colleagues also recently demonstrated an association between infantile wheezing RSV and RV illnesses and current wheezing at age 5 years; however, their finding was limited to children with early allergic sensitization (6). They also associated RV wheezing in infancy and asthma at age 5 years, but this association was no longer significant when the results were controlled for other risk factors (6). In contrast, in the COAST cohort, RV wheezing illnesses in infancy and early childhood alone were a significant risk factor for asthma at age 6 years, and this relationship was enhanced after controlling for other risk factors. One potential explanation for the differences in study results is the improved viral detection rate in COAST compared with other cohorts, particularly with respect to RVs. The PCR primers used in this system have proven to detect all 101 known strains of RV (12). Furthermore sequencing of PCR products from a subset of specimens in this study has led to the discovery of 26 additional strains of RV, including 9 whose 5' sequences cluster into a group that is distinct from group A and B RVs (17). Recent observations by Devulapalli and colleagues suggested that the number and/or persistence of bronchial obstructive episodes in the first 2 years of life are important predictors of subsequent asthma risk at age 10 years (18). Although viral diagnostics were not performed, these findings suggest that respiratory illness burden in early life is closely associated with asthma risk. We evaluated a number of outcomes that provide further insight into these relationships. First, numbers of documented infections during routine scheduled visits were not related to subsequent asthma. Second, illnesses had to be accompanied by wheezing in order for a lower respiratory illness to be a significant determinant of asthma risk at age 6 years. A novel aspect of our findings is that wheezing with specific viral pathogens (i.e., RV vs. other viruses) conferred differential rates of asthma risk. Importantly, the burden of RV wheezing illnesses increased during the first 3 years of life for children who went on to develop asthma (Figure 1). By Year 3, children who wheezed three or more times had invariably wheezed with RV. Our data clearly link RV wheezing illnesses during early life and increased asthma risk in later childhood. These findings therefore raise the question: do early RV illnesses actually cause asthma? Alternately, RV wheezing episodes might instead serve to reveal children who are already predisposed to this disease on the basis of abnormal lung physiology and/or immune responses. In support of the latter hypothesis, it has been demonstrated that host-related factors related to low lung function and immunoregulation can enhance susceptibility to virus-induced wheezing (19, 20). For example, low interferon responses in stimulated blood mononuclear cells increase the risk of viral illnesses and wheezing in infancy (14, 21, 22). These two hypotheses are not mutually exclusive, and we propose that, in the genetically susceptible host, RV wheezing illnesses could cause pathologic effects in the airways that promote asthma. Additional studies are needed to resolve this important question. In conclusion, it has long been recognized that infants who wheeze with respiratory viruses, and particularly those few infants who are hospitalized, are at increased risk of subsequent asthma. Our results expand this paradigm by focusing on outpatient illnesses and demonstrate that the etiology and severity of viral respiratory infections significantly predict asthma development in a high-risk cohort. It is noteworthy that, among outpatient illnesses, which are much more common than those requiring hospitalization, RV-associated wheezing is a better indicator of asthma risk than RSV-associated wheezing. A major goal for future research efforts should therefore be to define host and viral factors that promote wheezing RV illnesses in early childhood. Furthermore, additional studies are needed to determine whether RV wheezing illnesses in early childhood predict specific phenotypes of asthma (atopic vs. nonatopic) throughout childhood and beyond. These studies could provide novel therapeutic targets related to the initiation of and/or progression from early viral wheezing episodes to the subsequent development of childhood asthma.
Supported by National Institutes of Health grants R01 HL61879, P01 HL70831, and M01 RR03186. This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org Originally Published in Press as DOI: 10.1164/rccm.200802-309OC on June 19, 2008 Conflict of Interest Statement: D.J.J. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. R.E.G. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.D.E. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. K.A.R. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. E.L.A. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. T.E.P. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.C.P. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. W.-M.L. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. P.A.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. E.R. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. K.T.C.-D. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. L.P.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. D.F.D. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. C.J.T. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. J.E.G. serves on the Scientific Advisory Board for Eragen Biosciences and has stock options in the company. He received $1,200 in consulting fees in 2007. R.F.L. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. Received in original form February 21, 2008; accepted in final form June 19, 2008
This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TOP
ABSTRACT
AT A GLANCE COMMENTARY
